Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    ... and response to erythroid stimulating agents or lenalidomide has not been investigated. The HepG2 hepatoma cell line was ... (125 prior to erythroid stimulating agents and 186 prior to lenalidomide). Serum concentrations of S100A9, S100A8, TNFα, IL1β and Epo ...

    Research Article last updated 10/20/2017 - 9:16am.

  2. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

    ... with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50 mg) has activity as frontline therapy in elderly AML but ... included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50 mg) on days 1-28 of 42-day cycles. The primary endpoint ...

    Research Article last updated 11/02/2016 - 9:17am.

  3. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have ... only in the European Union. Mounting evidence suggests that lenalidomide is effective not only in reducing red blood cell (RBC) ...

    Research Article last updated 12/08/2015 - 1:06pm.

  4. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

    ... MDS patients achieve an erythroid response with lenalidomide in 25-30% of cases. Addition of erythropoiesis-stimulating ... identified in the diseased clone on response to lenalidomide and the drug effects on clonal evolution remain unknown. We ...

    Research Article last updated 04/29/2016 - 11:33am.

  5. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... Introduction: Lenalidomide is an IMiDs? oral immunomodulatory compound developed for the ... syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response may be important to optimize responses and ...

    Research Article last updated 11/16/2011 - 2:10pm.

  6. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine are active in MDS patients, and may ... malignant clone . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging results; however, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

    ... and decreased miR-145 and miR-146a expression. Lenalidomide is an immunomodulatory agent that selectively suppresses the ... of MDM2 with subsequent enhanced P53 degradation. Lenalidomide showed success in low- and intermediate-1-risk MDS as reported in ...

    Research Article last updated 04/17/2014 - 11:29am.

  8. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... Lenalidomide has proven efficacy and safety and has been shown to reduce ... System low- or intermediate-1-risk MDS who began lenalidomide therapy between April 2002 and June 2003 as part of the MDS-001 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

    ... agents, and the duration of response is often limited. Lenalidomide , a second-generation immunomodulatory drug (IMiD), is ... MDS patients with deletion 5q chromosomal abnormality. Lenalidomide also has meaningful clinical activity in lower-risk patients ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... immunomodulatory agents (imids) thalidomide and lenalidomide may induce transfusion independence . This guideline ... abstracts met eligibility criteria. CONCLUSIONS: Lenalidomide is recommended as first line therapy in lower risk del5q MDS. ...

    Research Article last updated 10/01/2012 - 10:04am.